Jafron Biomedical Co.,Ltd. (SHE:300529)

Jafron Biomedical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,473	2,670	1,919	2,487	2,671	1,946
Other Revenue	7.33	7.33	3.42	4.54	4.5	4.64
Revenue	2,481	2,677	1,922	2,491	2,675	1,951
Revenue Growth (YoY)	18.47%	39.27%	-22.84%	-6.88%	37.15%	36.24%
Cost of Revenue	467.14	520.26	390.89	440.36	402.12	288
Gross Profit	2,014	2,157	1,531	2,051	2,273	1,663
Selling, General & Admin	836.62	881.19	787.89	838.78	729.46	587.45
Research & Development	238.9	240.09	245.38	253.91	173.77	80.76
Other Operating Expenses	55.89	37.29	24.61	33.72	39.56	28.24
Operating Expenses	1,130	1,159	1,048	1,124	949.55	697.27
Operating Income	883.48	997.98	482.98	926.66	1,324	965.51
Interest Expense	-61.6	-63.71	-54.33	-36.04	-8.91	-
Interest & Investment Income	58.81	73.09	87.96	63.79	56.5	44.01
Currency Exchange Gain (Loss)	0.78	0.78	1.22	1.07	-0.81	-0.37
Other Non Operating Income (Expenses)	6.84	-1.73	-2.12	-0.5	-5.34	-2.36
EBT Excluding Unusual Items	888.31	1,006	515.71	954.97	1,365	1,007
Impairment of Goodwill	-5.2	-5.2	-25.61	-6.26	-	-
Gain (Loss) on Sale of Investments	12.82	1.02	-	-0.01	0.01	-
Gain (Loss) on Sale of Assets	0.27	3.64	6.72	0.86	0.98	-
Asset Writedown	-0.65	-1.04	-1.46	-1.61	-1.15	-0.48
Other Unusual Items	-3.39	2.13	25.66	68.85	42.14	25.64
Pretax Income	892.16	1,007	521.02	1,017	1,407	1,032
Income Tax Expense	173.72	192.78	95.3	135.86	211.38	158.95
Earnings From Continuing Operations	718.44	814.19	425.72	880.95	1,196	873
Minority Interest in Earnings	5.78	6.01	10.77	8.62	0.97	2.24
Net Income	724.21	820.2	436.49	889.56	1,197	875.24
Net Income to Common	724.21	820.2	436.49	889.56	1,197	875.24
Net Income Growth	38.02%	87.91%	-50.93%	-25.67%	36.74%	53.33%
Shares Outstanding (Basic)	781	781	794	794	803	796
Shares Outstanding (Diluted)	781	781	794	794	803	810
Shares Change (YoY)	-1.94%	-1.57%	-0.08%	-1.12%	-0.89%	2.22%
EPS (Basic)	0.93	1.05	0.55	1.12	1.49	1.10
EPS (Diluted)	0.93	1.05	0.55	1.12	1.49	1.08
EPS Growth	40.75%	90.91%	-50.89%	-24.83%	37.96%	50.00%
Free Cash Flow	621.24	815.85	669.49	407.91	712	600.37
Free Cash Flow Per Share	0.80	1.04	0.84	0.51	0.89	0.74
Dividend Per Share	0.800	0.800	0.400	0.670	0.900	0.660
Dividend Growth	100.00%	100.00%	-40.30%	-25.56%	36.36%	39.33%
Gross Margin	81.17%	80.57%	79.67%	82.33%	84.97%	85.24%
Operating Margin	35.61%	37.28%	25.12%	37.19%	49.48%	49.49%
Profit Margin	29.19%	30.64%	22.71%	35.70%	44.73%	44.87%
Free Cash Flow Margin	25.04%	30.47%	34.83%	16.37%	26.61%	30.78%
EBITDA	1,013	1,120	573.43	995.72	1,373	1,002
EBITDA Margin	40.83%	41.82%	29.83%	39.97%	51.32%	51.38%
D&A For EBITDA	129.5	121.69	90.44	69.07	49.25	36.73
EBIT	883.48	997.98	482.98	926.66	1,324	965.51
EBIT Margin	35.61%	37.28%	25.12%	37.19%	49.48%	49.49%
Effective Tax Rate	19.47%	19.14%	18.29%	13.36%	15.02%	15.40%
Revenue as Reported	2,481	2,677	1,922	2,491	2,675	1,951

Source: S&P Global Market Intelligence. Standard template. Financial Sources.